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Background: Treatment of severe aortic valve stenosis (SAVS) is a hot topic due to improved life 
expectancy of general population, improvement of diagnostic tools, and consequent increased number of 
patients requiring aortic valve surgery. Traditional aortic valve replacement and recent transcatheter aortic 
prosthesis implantation have reported comparable or non-inferior mortality in randomised controlled trials 
(RCTs). However, RCTs have the limitation of the predefined inclusion/exclusion criteria, and cannot 
completely reflect the ‘real clinical world’. Recently sutureless prostheses, often implanted via minimally 
invasive approaches, have been reported as an alternative strategy. However, their definitive impact on 
clinical results is not yet completely evaluated because of the limited sample size of patients population of 
most of published studies, based on monocentric patients series. 
Methods: The aim of this prospective multicentre registry including all patients referred for aortic valve 
surgery and treated with all available techniques is to obtain a ‘real-world’ scenario of the clinical results 
arising from current surgical options.
Results: The research protocol enrollment phase is ongoing. Therefore we have not yet results to publish. 
When available, the research findings deriving from E-AVR registry will be presented in the scientific 
community in international congresses and published in peer review international journals in the fields of 
cardiac surgery and cardiology.
Conclusions: This multicenter, prospective, European registry has been designed with the aim to cast light 
on a lot of controversial issues, particularly those regarding the impact of patient baseline risk factors as well 
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Introduction
The prevalence of aortic valve stenosis (AS) can be 
correlated with the increase of life expectancy (1,2). Surgical 
aortic valve replacement (SAVR) has recognized the gold 
standard for AS, based on scientific evidence of published 
studies reporting improvement in symptoms and survival 
(3,4). This kind of surgery is performed with low morbidity, 
and is associated with durable efficacy results in the long-
term follow-up (1,2). 
For many years, the only available options in AS patients 
with prohibitive operative risk were maximized medical 
therapy or balloon valvuloplasty. However, the efficacy of 
these conservative therapies was limited to short-lasting 
symptomatic improvement, and balloon valvuloplasty is 
burdened from early failure with high need for repeat 
procedure conditioning poor short-term outcome.
Recent technological advances allowed transcatheter 
aortic valve replacement (TAVR) which proved to be an 
effective, alternative treatment modality to traditional SAVR 
in high-risk patients (5,6). Similarly, surgical TAVR have 
been reported good outcome-results in high-risk AS not 
amenable to interventional TAVR (5,7). Therefore, both 
traditional SAVR and surgical TAVR represent nowadays 
the surgical armamentarium for aortic valve replacement.
In the PARTNER trial cohort A, enrolling patients 
at high surgical risk, outcomes after TAVR and SAVR 
were similar up to 5 years in terms of overall mortality, 
cardiovascular-related mortality, stroke, or repeat hospital 
admission (7). Moderate or severe aortic regurgitation 
caused by paravalvular regurgitation was more common 
in patients who underwent TAVR and led to lower 
survival in the follow-up (8). The COREVALVE US trial 
reported results of TAVR in patients at increased surgical 
risk, demonstrating higher early and 2-year survival 
rates with self-expanding TAVR implantation compared 
with traditional surgery (9). Recently, the PARTNER 
2 Investigators Trial reported that intermediate-risk patients 
with severe symptomatic AS had similar results in terms of 
death or stroke at 2 years, independently from the fact to 
have received TAVR or SAVR. Moreover, both procedures 
resulted in a similar degree of improvement of cardiac 
symptoms (10). Another Italian nationwide prospective 
registry demonstrated comparable outcome between 
TAVR and SAVR in intermediate-risk patients (11), but 
superiority of SAVR vs. TAVR in 2- and 3-year mortality in 
an exploratory subanalysis of low-risk patients (12). 
Since TAVR is still burdened from periprocedural 
paravalvular leakage, due to the calcified native valve left 
in place, alternative approaches with the use of sutureless 
valves have been proposed after the earliest experiences. A 
number of sutureless valve prostheses have been developed 
to reduce cross-clamp times and are currently in clinical 
use (13-15). These sutureless valve prostheses may 
benefit of the conventional surgical approach allowing 
complete access to the aortic valve, in order to obtain 
complete decalcification of the annulus, and to create a 
pliable annulus. These findings may prevent paravalvular 
leakage, permit an appropriate sizing of the prosthesis 
into the annulus with shortened myocardial ischemia time. 
Implantation of sutureless valves has demonstrated safety 
and efficacy also through minimally invasive approaches, 
in order to improve inflammatory events and post-
operative morbidity related to prolonged extracorporeal 
circulation (16,17). Several studies compared the outcomes 
of sutureless valves with TAVR (in patients classified 
as moderate- to high-risk), and reported benefits with 
sutureless prostheses (18,19).
However, the long-term results after implantation of 
TAVR or sutureless prostheses remain still unknown. 
This issue is of particular interest because a lot of studies 
reported improved long-term excellent results of recent 
as treatment methods for SAVR, with or without coronary artery bypass grafting (CABG), on the prognosis 
after treatment. We believe that the information derived from this registry can provide deep knowledge on 
the causes that lead to adverse outcomes after SAVR, to avoid them, and finally to identify the best treatment 
option for SAVS for each patient.
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biological valve models (20,21), also in patients with an age 
younger than 65 (22), that is the threshold recommended 
by the recent European Association for Cardio-Thoracic 
Surgery (EACTS) and the European Society of Cardiology 
(ESC) guidelines (23). Therefore, data on the efficacy, safety 
and durability of these alternative biological prostheses 
are key-issues to extended the use of these less invasive 
procedure to low-risk and younger patients with AS.
Finally, it is well known that many patients with severe 
AS have concomitant significant coronary artery disease 
(CAD). Although the most consolidated strategy for 
these patients is contemporary SAVR and coronary artery 
bypass grafting (CABG), the introduction of TAVR has 
considerably shifted the potential optimal treatment options 
in this subset of patients, leaving some questions on the 
efficacy and late outcome unanswered. Moreover, the best 
interventional treatment choice for this scenario has yet to 
be verified, given the fact that some authors are favorable 
to combined PCI + TAVR, others to staged PCI and then 
TAVR, and finally other authors recommend reversed 
timing first with TAVR and then PCI (24,25). 
Thus, robust medium- and long-term efficacy, and 
quality of life (QoL) data of TAVR compared with standard 
and innovative SAVR remain an important issue to further 
refine the clinical selection process of TAVR candidates. It 
seems reasonable that benefits and risks of TAVR compared 
with SAVR must be assessed under real world conditions. 
Therefore, data from a multicentre, real-world registry may 
provide information to support future recommendations on 
the use of these innovative devices.
Aim and design of the study
The results obtained by cardiac surgery can be improved 
with the implementation of present surgical methods and 
the development of new techniques based on the knowledge 
derived from large clinical datasets (26). 
The main strengths of prospective clinical registries 
include a high objective scientific meaning because 
collected data are drawn from the standard clinical practice. 
Moreover, prospective clinical registries allow large sample 
size of patient population and then a better estimation 
of event rates. Thus, the researchers can investigate 
hard endpoints and outcomes studying general patient 
populations from different institutions with reduced 
exclusion criteria. Importantly, clinical registries can collect 
and analyze data on long-term outcome generally exceeding 
the study period of a prospective randomized trial (26). 
They are more practical than randomized controlled trials, 
require less resources, and have less rigid inclusion and 
exclusion criteria for patient enrollment (thus resembling 
better the so-called “real world” practice). Finally, results 
derived from registries have more scientific significance 
when study populations derive from different geographic 
areas and heterogeneous baseline clinical characteristics and 
undergo different perioperative treatment strategies.
The rationale of this E-AVR registry is to collect 
prospectively data on baseline characteristics, perioperative 
variables and postoperative outcome of patients undergoing 
SAVR, isolated or with concomitant CAD, in several 
European centers of cardiac surgery. Patients will be 
followed-up for at least 5 years after treatment. 
The main aims of this study are the following:
	A comparative analysis of the early and late outcome 
with different surgical aortic valve prostheses;
	A specific focus on the comparison between 
sutureless biologic valve prostheses and conventional 
biological valve prostheses (either stented and 
stentless);
	Comparison of third generation stented biologic 
valve prostheses with second generation TAVR;
	Comparison of sutureless biologic valve prostheses 
with second generation TAVR; 
	Evaluation of results with different approaches 
fo r  SAVR,  i . e . ,  s t andard  fu l l  s t e rno tomy, 
minithoracotomy, ministernotomy, trans-apical and 
-aortic TAVR;
	Evaluation of limits and benefits of combined SAVR 
and CABG vs. SAVR and staged PCI or TAVR and 
staged/reversed stage/combined PCI;
	Identification of indication criteria for SAVR based 
on baseline characteristics;
	In case of future merging with other ongoing 
prospective registries of interventional TAVR, 
comparative analyses between interventional 
TAVR and surgical SAVR and/or TAVR will be 
accomplished.
This study has been registered in Clinicaltrials.gov. 
NCT03143361.
Methods
The E-AVR is an observational registry study designed to 
collect prospectively data on patients undergoing aortic 
valve surgery from 17 heart surgery centers belonging to 
University or community hospitals, and located in seven 
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countries (France, Germany, Italy, Spain, Switzerland, UK, 
and USA).
Inclusion criteria
Patients aged more than 18 years undergoing isolated 
primary or re-do SAVR, with or without associated CABG, 
and regardless of the etiology of the aortic valve disease, are 
eligible for inclusion in this prospective registry. 
Exclusion criteria
Patients receiving concomitant mitral, tricuspid or aortic 
surgery, or other associated cardiac surgical procedures 
other than CABG will be excluded from this registry.
Patients will be enrolled in each institution, and their 
data collected in a dedicated database. The enrollment 
period will be 24 months. Patients will be followed-up 
30 days, 6 months, 1 year, and then every year up to 5 years 
after surgery.
Data management and monitoring
Data will be stored in a dedicated CRF with predefined 
variables. Analysis and periodic auditing of data will be 
accomplished by an independent Central Core Laboratory. 
Auditing of quality of data will be performed every 
6 months by checking 10% of patients. The merged and 
checked dataset will be available to all E-AVR investigators 
for scientific analyses.
Statistical methods
An independent central statistical Core Lab will accomplish 
all the statistical analyses derived from this registry.
Continuous variables will be reported as mean ± SD, or 
median and interquartile range. Dichotomous and nominal 
variables will be reported as counts and percentages. 
Missing data will not be replaced. Univariate analysis will 
be performed using the Mann-Whitney U test, Student’s 
t-test, Kruskall-Wallis test, Wilcoxon test, Fisher exact test, 
Chi-square test and Kaplan-Meier test, when indicated. 
Multivariable analyses will be performed using logistic, 
linear and ordinal regression methods as well as the 
Cox-proportional hazards method. Propensity score as 
covariate or one-to-one propensity score matching will 
be adopted to adjust significant differences between study 
groups. Matching will be performed using a caliper width 
of 0.2 of the standard deviation of logit of the propensity 
score. Multiple propensity score adjusted analysis will be 
performed in case of multiple study groups. A Bayesian 
hierarchical approach will be used in case of significant 
between-centers variability. 
Early and late endpoints
Endpoints will be defined according to current guidelines, 
and in particular according to Valve Academic Research 
Consortium (VARC)-2 (27) and mortality and morbidity 
after cardiac valve procedures guidelines (28). More in 
detail the following outcome variables will be collected:
	Early endpoints of the E-AVR registry: 
(I) in-hospital mortality and 30-day mortality; 
(II) post-operative stroke; 
(III) postoperative need for inotropes; 
(IV) postoperative need of intra-aortic balloon 
pump (IABP) or extracorporeal mechanical 
oxygenation (ECMO); 
(V) sternal/thoracic wound infection; 
(VI) blood losses and use of blood products; 
(VII) nadir hematocrit; 
(VIII) nadir hemoglobin; 
(IX) resternotomy for bleeding; 
(X) atrial fibrillation; 
(XI) complete atrioventricular block; 
(XII) need for new pacemaker (PM) implantation; 
(XIII) acute kidney injury; 
(XIV) acute myocardial infarction; 
(XV) early repeat surgery; 
(XVI) pericardial effusion requiring surgical 
revision; 
(XVII) length of stay in the intensive care unit 
(ICU); 
(XVIII) in-hospital length of stay;
(XIX) echocardiographic data of prosthesis 
performance; 
	Late endpoints: 
(I) overall mortality; 
(II) cardiac-related mortality; 
(III) stroke; 
(IV) myocardial infarction; 
(V) reintervention on the aortic prosthesis; 
(VI) repeat revascularization [with percutaneous 
coronary intervention (PCI) or CABG]; 
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(VII) thromboembolic events;
(VIII) bleeding events; 
(IX) structural valve deterioration; 
(X) paravalvular leakage; 
(XI) prosthetic endocarditis; 
(XII) implantable cardioverter-defibrillator/
pacemaker; 
(XIII) major adverse cardiac and cerebrovascular 
events (MACCE), defined as the composite 
endpoint including any of the following 
adverse events: overall death, stroke, 
myocardial infarction, PCI, and CABG; 
(XIV) QoL defined according to: (preoperative, 
discharge, 6 months, 1 year, 5 years SF-8 
questionnaire). QoL will be assessed 
during follow-up visits at outpatient clinics 
or, at least, by telephone interview;
(XV) echocardiographic data of prosthesis 
performance. 
Echocardiographic data of prosthesis performance are 
defined according to the VARC-2 definitions (27).
Dissemination policy
The research findings deriving from E-AVR registry 
wil l  be presented in the scienti f ic  community in 
international congresses and published in peer review 
international journals in the fields of cardiac surgery 
and cardiology.
Steering committee
It is constituted by a principal investigator and a 
representing member from each of the participating 
centers. The members of the steering committee have 
the responsibility for the quality of data through local and 
periodic audit. The steering committee will evaluate each 
study proposal and accept/reject it by voting after having 
evaluated the study design and discussed on its feasibility. 
Investigators will be eligible for authorship if they 
contributed substantially to study planning, data collection, 
data analysis and interpretation, writing and critical 
revision of the manuscripts. The principal investigator will 
finalize the database and will guarantee that each steering 
committee member will have a copy of the overall database. 
Analyses will be performed or monitored by an independent 
Central Core Statistic Laboratory. 
Ethical issues
The study has been approved by the local Institutional 
Review Board/Ethical Committee of each participating 
centre, according to local or national guidelines for 
approval of registry studies. Patient’s informed consent will 
be mandatory. 
Results
The research protocol enrollment phase is ongoing. 
Therefore we have not yet results to publish. When available, 
the research findings deriving from E-AVR registry will 
be presented in the scientific community in international 
congresses and published in peer review international 
journals in the fields of cardiac surgery and cardiology.
Conclusions
This multicenter, prospective, European registry has been 
designed with the aim to cast light on a lot of controversial 
issues, particularly those regarding the impact of patient 
baseline risk factors as well as treatment methods for SAVR, 
with or without CABG, on the prognosis after treatment. 
We believe that the information derived from this registry 
can provide deep knowledge on the causes that lead to 
adverse outcomes after SAVR, to avoid them, and finally 
to identify the best treatment option for severe aortic valve 
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